Ernst and Young round table identifies new investors
This article was originally published in Clinica
Executive Summary
There is a new type of investor in the biotech industry, according to a panel assembled as part of the 12th Annual Biotechnology Industry Report, published by the global accountancy company, Ernst & Young. There are those, particularly in Europe, who are following a trend set in the early 1990s in the US, by investing solely in the sector. Others have made an investment calculation based on the results of clinical trials, despite the fact that those trials may not be favourable to the companies concerned.